NCT04726787Active, not recruiting
RadiothErapy priMIng for CAR-T
Source: ClinicalTrials.gov · Last updated 9 Dec 2024
Brief summary (registry, in English)
The REMIT trial will investigate radiotherapy as a preferred bridging method prior to Tisagenlecleucel infusion in patients with relapsed or refractory Diffuse Large B Cell Lymphoma
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 6 (actual)
- First submitted
- 20 Jan 2021
- Start date
- 18 Aug 2022
- Primary completion date
- 5 Jul 2023
- Lead sponsor
- University College, London
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT04726787
What you commit to
- Study type: Interventional
- Participants enrolled: 6
- From 18 Aug 2022 to the primary completion date, 5 Jul 2023
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radiotherapy at location/dose that would interfere with application of radiotherapy or outcome measures in this trial
- Previous therapy with any genetically modified autologous or allogeneic T-cell immunotherapy, unless treated with doses of genetically modified autologous or allogeneic T-cell immunotherapy within an abandoned dosing cohort in a first in human dose-escalation phase I clinical trial
Other
- Women who are pregnant or breast feeding
Who the study is looking for
- Written informed consent
- Age ≥ 18 years
- Histologically proven DLBCL, including transformed follicular or marginal zone lymphoma
- Measurable disease on cross-sectional imaging that is at least 1.5cm in the longest diameter and measurable in two perpendicular dimensions
- Relapsed/refractory after 2 or more standard immuno-chemotherapies
- Approved to receive Tisagenlecleucel as per the licenced indication
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Disease accessible for repeat biopsies (Selected patients only)
- Disease amenable to radiotherapy as assessed by the treating clinical oncologist
- Willing and able to comply with the requirements of the protocol, including contraceptive advice as per the protocol
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St James's University Hospital Coordinator of this site? Confirm its status | Leeds | United Kingdom | Unknown status |
| Kings College Hospital Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| Freeman Hospital Coordinator of this site? Confirm its status | Newcastle | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.